FierceBiotech1d
Eisai, Eli Lilly didn't disclose heightened brain injury risk to Alzheimer's trial patients: NYT
A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
STAT2d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
Campaign US4h
How Lilly is building a brand people trust
Lina Polimeni, chief corporate brand officer at Lilly, notes that public perception of the company has historically been ...
Novo Nordisk's semaglutide could also be effective against Alzheimer's
A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...
FiercePharma2d
Red light, green light: England's NICE not sold on Lilly's Kisunla despite UK approval
Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...